Victor V Lima1, Saiprasad M Zemse2, Chin-Wei Chiao3, Gisele F Bomfim4, Rita C Tostes5, R Clinton Webb2, Fernanda R Giachini6. 1. Institute of Biological Sciences and Health, Federal University of Mato Grosso, Barra do Garças, MT, Brazil. 2. Department of Physiology, Georgia Regents University, Augusta, GA, United States. 3. Department of Pharmacology, National Taiwan University, Taipei, Taiwan. 4. Health Sciences Institute, Federal University of Mato Grosso, Barra do Garças, MT, Brazil. 5. Department of Pharmacology, Ribeirao Preto Medical School, University of Sao Paulo, Ribeirao Preto, SP, Brazil. 6. Institute of Biological Sciences and Health, Federal University of Mato Grosso, Barra do Garças, MT, Brazil. Electronic address: fernandagiachini@hotmail.com.
Abstract
AIMS: Interleukin-10 (IL-10) is a multi-functional cytokine with potent anti-inflammatory properties. We hypothesized that IL-10 limits increased RhoA/Rho-kinase signaling and vascular reactivity in arteries from angiotensin II (Ang II) hypertensive mice. MAIN METHODS: Wild type (WT) and IL-10 knockout ((-/-)) mice were infused with Ang II (90ng/min) for 14days. Additionally, WT mice were infused with Ang II and simultaneously infused with exogenous IL-10 (0.5ηg/min, 14days). Aortic rings were mounted in a myograph and concentration-response curve to phenylephrine (PE) were evaluated. KEY FINDINGS: After Ang II infusion, blood pressure responses, but not maximal contraction to PE, was greater in IL-10(-/-) mice, compared to WT. Rho-kinase inhibition (Y-27632; 10μM) resulted in a more evident reduction of PE-induced contraction in WT hypertensive mice, when compared to IL-10(-/-) hypertensive mice. IL-10 exogenous infusion prevented the blood pressure increase in Ang II-infused WT mice. The augmented PE-contraction observed in aorta from WT mice infused with Ang II was also prevented by exogenous infusion of IL-10. Additionally, Rho-kinase inhibition (Y-27632; 10μM) abolished the differences in the contractile response to PE between these groups. SIGNIFICANCE: These results demonstrate that IL-10 counteracts both the pressoric activity of Ang II as well as vascular dysfunction associated with hypertension, partially, modulating the RhoA-Rho kinase pathway. Strategies to enhance IL-10 levels during hypertension may enhance the benefits provided by regular treatments.
AIMS: Interleukin-10 (IL-10) is a multi-functional cytokine with potent anti-inflammatory properties. We hypothesized that IL-10 limits increased RhoA/Rho-kinase signaling and vascular reactivity in arteries from angiotensin II (Ang II) hypertensivemice. MAIN METHODS: Wild type (WT) and IL-10 knockout ((-/-)) mice were infused with Ang II (90ng/min) for 14days. Additionally, WT mice were infused with Ang II and simultaneously infused with exogenous IL-10 (0.5ηg/min, 14days). Aortic rings were mounted in a myograph and concentration-response curve to phenylephrine (PE) were evaluated. KEY FINDINGS: After Ang II infusion, blood pressure responses, but not maximal contraction to PE, was greater in IL-10(-/-) mice, compared to WT. Rho-kinase inhibition (Y-27632; 10μM) resulted in a more evident reduction of PE-induced contraction in WT hypertensivemice, when compared to IL-10(-/-) hypertensivemice. IL-10 exogenous infusion prevented the blood pressure increase in Ang II-infused WT mice. The augmented PE-contraction observed in aorta from WT mice infused with Ang II was also prevented by exogenous infusion of IL-10. Additionally, Rho-kinase inhibition (Y-27632; 10μM) abolished the differences in the contractile response to PE between these groups. SIGNIFICANCE: These results demonstrate that IL-10 counteracts both the pressoric activity of Ang II as well as vascular dysfunction associated with hypertension, partially, modulating the RhoA-Rho kinase pathway. Strategies to enhance IL-10 levels during hypertension may enhance the benefits provided by regular treatments.
Authors: Matti Adam; Nigel Geoffrey Kooreman; Ann Jagger; Markus U Wagenhäuser; Dennis Mehrkens; Yongming Wang; Yosuke Kayama; Kensuke Toyama; Uwe Raaz; Isabel N Schellinger; Lars Maegdefessel; Joshua M Spin; Jaap F Hamming; Paul H A Quax; Stephan Baldus; Joseph C Wu; Philip S Tsao Journal: Arterioscler Thromb Vasc Biol Date: 2018-08 Impact factor: 8.311
Authors: Francine Z Marques; Geoffrey A Head; Madeleine R Paterson; Kristy L Jackson; Malathi S I Dona; Gabriella E Farrugia; Bruna Visniauskas; Anna M D Watson; Chad Johnson; Minolfa C Prieto; Roger G Evans; Fadi J Charchar; Alexander R Pinto Journal: Hypertension Date: 2021-09-20 Impact factor: 10.190
Authors: Alecsander F Bressan; Gisele A Fonseca; Rita C Tostes; R Clinton Webb; Victor Vitorino Lima; Fernanda Regina Giachini Journal: Fundam Clin Pharmacol Date: 2018-09-07 Impact factor: 2.748
Authors: Hajrunisa Cubro; Karl A Nath; Sonja Suvakov; Oscar Garcia-Valencia; Santosh Parashuram; Wendy M White; Tracey L Weissgerber; Meryl C Nath; Natasa M Milic; Fernando Sontag; Livius V d'Uscio; Yi Zhu; James L Kirkland; Tamar Tchkonia; Mariam P Alexander; Reade A Quinton; Zvonimir S Katusic; Joseph P Grande; Vesna D Garovic Journal: Kidney Int Date: 2020-11-02 Impact factor: 10.612